Hudson Bay Capital Management LP Sells 14,346 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Hudson Bay Capital Management LP cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 48.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,006 shares of the biopharmaceutical company’s stock after selling 14,346 shares during the quarter. Hudson Bay Capital Management LP’s holdings in Regeneron Pharmaceuticals were worth $10,689,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of REGN. OFI Invest Asset Management bought a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $28,000. Rakuten Securities Inc. boosted its position in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 15 shares in the last quarter. Avalon Trust Co bought a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $36,000. Crowley Wealth Management Inc. bought a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $36,000. Finally, Private Wealth Management Group LLC boosted its position in Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 39 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on REGN shares. JPMorgan Chase & Co. cut their price objective on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating on the stock in a research report on Monday, March 31st. Piper Sandler dropped their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating on the stock in a research report on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $695.00 price target on the stock. Finally, BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $865.00 to $800.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, eighteen have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $892.60.

Regeneron Pharmaceuticals Stock Down 3.6%

REGN opened at $527.78 on Monday. The firm has a 50-day simple moving average of $613.08 and a two-hundred day simple moving average of $693.43. Regeneron Pharmaceuticals, Inc. has a 52 week low of $517.48 and a 52 week high of $1,211.20. The company has a market capitalization of $57.70 billion, a PE ratio of 13.79, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same period last year, the company earned $9.55 EPS. The firm’s revenue for the quarter was down 3.7% on a year-over-year basis. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.67%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.